Skip to main content
VulnerabilityPublished

CVE-2026-1029: IBM Common Licensing · Cross-site Scripting

Affects IBM Common LicensingSource CVE Database V5

0
Compare

Not known to be exploited · CVSS 5.4 Medium.

Data as of 2 Nov 2026, 10:58 UTC

CVSS 3.1 base score
5.4Medium
How severe the flaw is on the 0–10 CVSS scale.
EPSS
0.2% chance of exploitation in 30 days – higher than 13% of CVEsExploit Prediction Scoring System: the likelihood attackers will use this flaw soon.
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:N

Exploitation evidence

  1. Disclosed: evidence found.

    CVE published 18 Sep 2026

  2. Detectable: no evidence on record.

    No public nuclei template indexed

  3. Weaponized: no evidence on record.

    No public exploit code indexed in Metasploit or Exploit-DB

  4. Exploited in the wild: no evidence on record.

    Not in CISA KEV and no source reports exploitation

  5. Observed by OffSeq Mirage: no evidence on record.

    No attack traffic recorded by OffSeq Mirage sensors

A missing step is not evidence of safety. Sources: cve.org (opens in a new tab), the Metasploit, Exploit-DB and nuclei-templates index as of 2 Nov 2026.

What to do

Affected software

ProductAffectedFixed in
IBMCommon LicensingAffected
  • Agent 9.0 – ART 9.0.0.2
6 affected builds
Fixed in–

CPE configurations (2)

  • cpe:2.3:a:ibm:common_licensing:agent:*:*:*:*:*:*:*
  • cpe:2.3:a:ibm:common_licensing:art:*:*:*:*:*:*:*

AI-suggested

Until a fix is available, users should exercise caution with web UI inputs and restrict access to trusted users only.

Description

IBM Common Licensing Agent 9.0, Agent 9.0.0.1, Agent 9.0.0.2, ART 9.0, ART 9.0.0.1, and ART 9.0.0.2 is vulnerable to cross-site scripting. This vulnerability allows users to embed arbitrary JavaScript code in the Web UI thus altering the intended functionality potentially leading to credentials disclosure within a trusted session.

References

Community reviews

Loading reviews…